SEC Form 4 · accession 0001209191-18-010564
Vaxart, Inc. · VXRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M Harland
Officer — Chief Financial Officer
Period of report
Feb 13, 2018
Accepted (ET)
Feb 15, 2018 · 8:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000072444
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $8.03 | Feb 13, 2018 | A | 9,563 | A | — | May 8, 2024 | Common Stock | 9,563 | 9,563 | D |
| Stock Option (right to buy)F3 | $17.49 | Feb 13, 2018 | A | 8,255 | A | — | Jul 23, 2025 | Common Stock | 8,255 | 8,255 | D |
| Stock Option (right to buy)F4 | $12.98 | Feb 13, 2018 | A | 4,087 | A | — | Mar 25, 2026 | Common Stock | 4,087 | 4,087 | D |
| Stock Option (right to buy)F5 | $4.07 | Feb 13, 2018 | A | 7,047 | A | — | Jun 24, 2027 | Common Stock | 7,047 | 7,047 | D |
Explanation of responses
- F1Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split").
- F2On May 8, 2014, Reporting Person was granted an option to purchase 475,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,563 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $8.03 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of March 24, 2014 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
- F3On July 23, 2015, Reporting Person was granted an option to purchase 410,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.35 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 8,255 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $17.49 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 30, 2015 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
- F4On March 25, 2016, Reporting Person was granted an option to purchase 203,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.26 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 4,087 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $12.98 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of March 24, 2016 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
- F5On June 24, 2017, Reporting Person was granted an option to purchase 350,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.08 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,047 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $4.07 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 14, 2017 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.